<DOC>
	<DOCNO>NCT00410163</DOCNO>
	<brief_summary>To investigate safety efficacy two dose regime ofatumumab combination chemotherapy previously untreated patient B-CLL</brief_summary>
	<brief_title>Ofatumumab With Fludarabine Cyclophosphamide B-CLL Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients active BCLL indication treatment 2 . Age ≥ 18 year 3 . Following receipt verbal write information study , patient must provide sign informed consent study related activity carry 1 . Any previous treatment BCLL treatment consider active BCLL 2 . Glucocorticoid unless give dos ≤ 10 mg /day indication BCLL ( e.g . asthma ) 3 . Known transformation BCLL 4 . Known CNS involvement BCLL 5 . Past current malignancy , except : 1 . Cervical carcinoma Stage 1B less 2 . Noninvasive basal cell squamous cell skin carcinoma 3 . Malignant melanoma complete response duration &gt; 10 year 4 . Other cancer diagnose complete response duration &gt; 5 year 6 . Chronic current infectious disease require systemic treatment 7 . Clinically significant cardiac disease 8 . Significant concurrent , uncontrolled medical condition 9 . History significant cerebrovascular disease 10 . Known HIV positive 11 . Positive serology hepatitis B , unless due vaccination 12 . Leukapheresis , except safety measure chemotherapy 13 . ECOG Performance Status 3 4 14 . Patients time inclusion expect able complete ofatumumabFC regimen 15 . Patients receive treatment nonmarketed drug substance experimental therapy within 4 week prior Visit 1 16 . Current participation interventional clinical study 17 . Patients know suspected able comply study protocol ( e.g . due alcoholism , drug dependency psychological disorder ) 18 . Breast feeding woman woman positive pregnancy test Visit 1 19 . Women childbearing potential willing use adequate contraception one year last dose ofatumumab . Adequate contraception define hormonal birth control intrauterine device . For patient USA use double barrier method also consider adequate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>B-cell</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>fludarabine</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>